The success of chimeric antigen receptor (CAR)-T cell therapy has spurred interest in applying CAR technology to other immune cells in hopes of addressing some known limitations. With their intrinsic immune activity and favorable safety profile, natural killer (NK) cells have enormous potential for adoptive cellular therapy1. Unlike T cells, which require antigen sensitization and […]